Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.

BACKGROUND There is increasing evidence that suggests that particular histopathologic types of non-small-cell lung cancer (NSCLC) display distinct molecular characteristics. We analyzed, in lung squamous cell carcinoma (SCC) and adenocarcinoma (AC), the expression of 8 genes that constitute 2 previously reported prognostic expression signatures in NSCLC. METHODS Fresh-frozen tumor and normal lung samples were obtained at surgery from 135 patients with stage I-III NSCLC (89 (65.9%) SCC, 46 (34.1%) AC). Expression of CSF1 (colony stimulating factor for macrophages), carbonic anhydrase 9 (CA9), epithelial growth factor receptor (EGFR), dual specificity phosphatase 6 (DUSP6), v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3), monocyte to macrophage differentiation-associated (MMD), lymphocyte-specific protein tyrosine kinase (LCK) and signal transducer and activator of transcription 1 (STAT1) was assessed in SCC, AC, and in normal lung by quantitative reverse transcriptase - polymerase chain reaction (qRT-PCR). Metastasis-free survival was analyzed according to the median value of gene expression in the entire NSCLC cohort and separately in SCC and AC. RESULTS Expression of CA9, CSF1, DUSP6, STAT1, and MMD differed between NSCLC and normal lung. EGFR was more abundant in SCC compared with AC, whereas the reverse was true for DUSP6 and ERBB3. A high expression of CSF1 correlated with shorter metastasis-free survival in the entire NSCLC group (P = .016) and in SCC (P = .049) and AC (P = .034) cohorts. CONCLUSIONS Several genes considered prognostic in NSCLC showed significantly different expression in SCC and AC, and thus should be analyzed separately in these 2 subtypes for their prognostic significance. CSF1 is similarly expressed in SCC and AC, and portends a poor outcome in the entire group of patients with NSCLC, and in SCC and AC when considered separately.

[1]  Yarong Wang,et al.  Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. , 2007, Cancer research.

[2]  Yi Zhang,et al.  Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. , 2006, Cancer research.

[3]  Eric B Haura,et al.  Effects of IFN-gamma and Stat1 on gene expression, growth, and survival in non-small cell lung cancer cells. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[4]  W. Oyen,et al.  Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. , 2010, European urology.

[5]  H. Nakamura,et al.  Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis , 2005, Thorax.

[6]  G. Scagliotti,et al.  Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase , 2006, Cancer.

[7]  L. Anderson,et al.  The ERBB3 receptor in cancer and cancer gene therapy , 2008, Cancer Gene Therapy.

[8]  Yoko Yamamoto,et al.  Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. , 2010, European journal of cancer.

[9]  Mariano Provencio,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[10]  Hideaki Mitsui,et al.  Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. , 2009, The American journal of pathology.

[11]  Igor Jurisica,et al.  Three-gene prognostic classifier for early-stage non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Tyers,et al.  Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. , 2002, Cancer research.

[13]  Yi-Chen Lin,et al.  Tumor-associated macrophages: the double-edged sword in cancer progression. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Donna Richardson,et al.  Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Chi-Ying F. Huang,et al.  Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme , 2007, BMC Genomics.

[17]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[18]  E. Mallon,et al.  Breast cancer patients’ clinical outcome measures are associated with Src kinase family member expression , 2010, British Journal of Cancer.

[19]  R. Weichselbaum,et al.  STAT1 Pathway Mediates Amplification of Metastatic Potential and Resistance to Therapy , 2009, PloS one.

[20]  Bradley P. Coe,et al.  A sequence-based approach to identify reference genes for gene expression analysis , 2010, BMC Medical Genomics.

[21]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[22]  J. Pollard,et al.  A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.

[23]  J. Tostain,et al.  CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy , 2007, Clinical & Experimental Metastasis.

[24]  S. Novello,et al.  Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer , 2006, BMC cancer.

[25]  Marcin Skrzypski,et al.  Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung , 2008, Clinical Cancer Research.

[26]  W. Funk,et al.  PAQR Proteins: A Novel Membrane Receptor Family Defined by an Ancient7-Transmembrane Pass Motif , 2005, Journal of Molecular Evolution.

[27]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Busch,et al.  The prognostic impact of M‐CSF, CSF‐1 receptor, CD68 and CD3 in prostatic carcinoma , 2008, Histopathology.

[29]  G. Scagliotti,et al.  Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung , 2009, Clinical Cancer Research.

[30]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[31]  J. Subjeck,et al.  Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant , 2008, Molecular Cancer Therapeutics.

[32]  G. Scagliotti,et al.  Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  Zhao-You Tang,et al.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Hyung L. Kim,et al.  Covalent crosslinking of tumor antigens stimulates an antitumor immune response. , 2010, Vaccine.

[35]  E. Gorelik,et al.  Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes , 2010, Cancer Immunology, Immunotherapy.

[36]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[37]  D. Payan,et al.  Systematic identification of regulatory proteins critical for T-cell activation , 2003, Journal of biology.

[38]  A. Borczuk,et al.  Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. , 2010, Carcinogenesis.

[39]  Marcin Skrzypski,et al.  An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.

[40]  J. Pouysségur,et al.  Overexpression of carbonic anhydrase XII in tissues from resectable non‐small cell lung cancers is a biomarker of good prognosis , 2011, International journal of cancer.

[41]  Yong Qian,et al.  Confirmation of Gene Expression–Based Prediction of Survival in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[42]  Igor Jurisica,et al.  Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Biao He,et al.  A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies , 2012, The Lancet.

[44]  Marcin Skrzypski,et al.  A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[45]  J. Pouysségur,et al.  High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer , 2010, British Journal of Cancer.

[46]  N. Rioux-Leclercq,et al.  Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma , 2008, International journal of cancer.